Side Effects of the Biologic Agents for Psoriasis

Abstract

Get full access to this article

View all access options for this article.

References

Duhra

Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 1993 Mar; 28(3): 466–9.

Hoekstra

, van Ede

A.E.

, Haagsma

C.J.

, van de Laar

M.A.

, Huizinga

T.W.

, Kruijsen

M.W.

, Laan

R.F.

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003 May; 62(5): 423–6.

Lowe

N.J.

, Wieder

J.M.

, Rosenbach

, Johnson

, Kunkel

, Bainbridge

, Bourget

, Dimov

, Simpson

, Glass

, Grabie

M.T.

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996 Nov; 35(5 Pt 1): 710–9.

Hojo

, Morimoto

, Maluccio

, Asano

, Morimoto

, Lagman

, Shimbo

, Suthanthiran

Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999 Feb 11; 397(6719): 530–4.

Gupta

A.K.

, Goldfarb

M.T.

, Ellis

C.N.

, Voorhees

J.J.

Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol. 1989 Jun; 20(6): 1088–93.

Gronhoj Larsen

, Steinkjer

, Jakobsen

, Hjorter

, Brockoff

P.B.

, Nielsen-Kudsk

Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol. 2000 Dec; 143(6): 1164–9.

Weinberg

J.M.

, Saini

, Tutrone

W.D.

Biological therapy for psoriasis—the first wave: infliximab, etanercept, efalizumab, and alefacept. J Drugs Dermatol. 2002; 1(3): 303–310.

Stern

D.K.

, Tripp

J.M.

, Ho

V.C.

, Lebwohl

The use of systemic immune moderators in dermatology: an update. Dermatol Clin. 2005 Apr; 23(2): 259–300.

Gottlieb

A.B.

, Infliximab for psoriasis. J Am Acad Dermatol. 2003; 49: S112–S117.

10.

Chaudhari

, Romano

, Mulcahy

L.D.

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet. 2001; 357: 1842–1847.

11.

Infliximab [package insert]. Malvern, Pennsylvania: Centocor, Inc.; 2005.

12.

Bresnihan

, Cunnane

Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003; 29: 185–202.

13.

Keane

, Gershon

, Wise

R.P.

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345: 1098–1104.

14.

Mohan

, Edwards

E.T.

, Cupps

T.R.

, Oliverio

P.J.

, Sandberg

, Crayton

, Rishert

J.R.

, Siegel

J.N.

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec; 44(12): 2862–9.

15.

Hochberg

M.C.

, Lebwohl

M.G.

, Plevy

S.E.

, Hobbs

K.F.

, Yocum

D.E.

The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Semin Arthritis Rheum. 2005 Jun; 34(6): 819–36.

16.

Levine

, Kalman

, Mayer

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323: 236–241.

17.

Brown

S.L.

, Greene

M.H.

, Gershon

S.K.

Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002; 46: 3151–3158.

18.

Goffe

, Cather

J.C.

Etanercept: An overview. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl): S105–11. Review.

19.

Mease

P.J.

, Goffe

B.S.

, Metz

, VanderStoep

, Finck

, Burge

D.J.

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000; 356: 385–390.

20.

Weinblatt

M.E.

, Kremer

J.M.

, Bankhurst

A.D.

Trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340: 253–259.

21.

Etanercept [package insert]. Thousand Oaks, Calif.: Immunex Corp.; 2004.

22.

Gottlieb

A.B.

, Matheson

, Lowe

N.J.

, Zitnik

R.J.

Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol. 2002; 119: 234.

23.

Kinlen

Immunosuppressive therapy and acquired immunological disorders. Cancer Res. 1992; 52 Suppl: 5474–5476.

24.

Adalimumab [package insert]. Chicago III.: Abbott Laboratories, 2005.

25.

Krueger

, Gottlieb

, Miller

, Dedrick

, Garovoy

, Walicke

Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol. 2000; 115: 333.

26.

Cather

J.C.

, Menter

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther. 2003; 3(2): 361–370.

27.

Weinberg

J.M.

An Overview of Infliximab, Etanercept, Efalizumab, and Alefacept as Biologic Therapy for Psoriasis. Clinical Therapeutics. 2003; 25: 1–19.

28.

Efalizumab [package insert]. San Francisco, Calif.: Genentech, Inc.; 2005.

29.

Leonardi

Craig L.

(2004) Efalizumab in the treatment of psoriasis. Dermatologic Therapy. 17(5): 393–400.

30.

Gaylor

M.L.

, and Duvic

Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol. 2004; 3(1): 77–79.

31.

Pietrzak

, Chodorowska

, Bartkowiak-Emeryk

, Pietzrak

, Urban

, Juszkiewicz-Borowiec

, Miturska

Possibilities of using alefacept in the treatment of psoriasis. Ann Univ Mariae Curie Sklodowska. 2003; 58: 311–313.

32.

Nickoloff

B.J.

Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol. Symp Proc 2000; 5: 67–73.

33.

Gade

J.N.

Clinical update on alefacept: consideration for use in patients with psoriasis. J Manag Care Pharm. 2004; 10(3 Suppl B): S33–37.

34.

Gordon

K.B.

, and Langley

R.G.

Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003; 2(6): 624–628.

35.

Alefacept [package insert]. Cambridge, Mass.: Biogen IDEC Inc.; 2005.

36.

Lebwohl

, Enno

, Langley

, An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003; 139: 719–727.